Highlights • Co-primary endpoints achieved in pivotal trial deploying ReCell® in patients with severe burns • Positive results also seen in another supportive trial • Company on-track to file a PMA with the U.S. Food & Drug Administration in mid-2017 • Avita primed to execute on U.S. commercialization strategy as early as Q2 2018 Valencia, […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-18 13:44:502018-01-05 13:14:37Avita Medical Announces Positive Results from Pivotal Trial
Monday, May 15, 2017 4:01 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In parallel, we are seeking opportunities to advance our chronic rhinosinusitis (CRS) and preclinical cystic fibrosis (CF) programs, potentially through partnerships and/or non-dilutive funding.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-15 15:01:012018-01-05 13:14:43AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights
15/05/2017 – link here Adherium have come out on top at this year’s Hi-Tech Awards, claiming the coveted Hi-Tech Hardware Product award. Over 900 people attended the awards ceremony, which celebrates the successes of New Zealand hi-tech companies across 13 categories. In selecting Adherium as Most Innovative Hi-Tech Hardware Product, the international judges said, “Adherium has […]
Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has filed an Inter Partes Review (IPR) petition against US Patent No. 9,610,430 (the ‘430 patent) owned by Renovacare Sciences Corp., as […]
Wednesday, May 10, 2017 5:29 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its previously announced underwritten public offering. Total proceeds […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-10 15:16:112018-01-03 15:19:11AmpliPhi Biosciences Announces Closing of Public Offering
Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 10 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emergency deployment of its […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-10 15:13:092018-01-05 13:15:00Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario
Thursday, May 4, 2017 10:02 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an underwritten public offering of 6,956,522 shares of […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-04 15:19:262018-01-03 15:23:08AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants
Monday, May 1, 2017 6:50 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “stated that the clinical safety and effectiveness data collected during development, including from emergency case studies, could inform future discussions for clinical development and, ultimately, the regulatory pathway to approval.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-05-01 15:23:192018-01-05 13:15:04AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections
Man with desperate infection rescued 100 years after Canadian co-discovery of phages By Amina Zafar, CBC News Posted: Apr 28, 2017 8:14 PM ET Last Updated: Apr 29, 2017 7:32 AM ET – Link here It may seem like an unlikely option, but it was viruses that helped to save Tom Patterson when a superbug threatened his life. Patterson fell […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-04-28 13:19:592018-01-05 13:16:07‘The enemy of my enemy is my friend:’ Couple turns to viruses to beat back superbug
Tuesday, April 25, 2017 6:50 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “Intravenous applications of phage therapy to treat a terminally ill patient who was infected with a multidrug-resistant A. baumannii” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-04-25 13:51:352018-01-04 13:58:07AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference
Avita Medical Announces Positive Results from Pivotal Trial
/in Avita Medical, Portfolio CompaniesHighlights • Co-primary endpoints achieved in pivotal trial deploying ReCell® in patients with severe burns • Positive results also seen in another supportive trial • Company on-track to file a PMA with the U.S. Food & Drug Administration in mid-2017 • Avita primed to execute on U.S. commercialization strategy as early as Q2 2018 Valencia, […]
AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights
/in Armata Pharmaceuticals, Portfolio CompaniesMonday, May 15, 2017 4:01 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In parallel, we are seeking opportunities to advance our chronic rhinosinusitis (CRS) and preclinical cystic fibrosis (CF) programs, potentially through partnerships and/or non-dilutive funding.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development […]
Adherium wins “Most Innovative Hi-Tech Hardware Product Award’ at the 2017 NZ High Tech Awards
/in Adherium, Portfolio Companies15/05/2017 – link here Adherium have come out on top at this year’s Hi-Tech Awards, claiming the coveted Hi-Tech Hardware Product award. Over 900 people attended the awards ceremony, which celebrates the successes of New Zealand hi-tech companies across 13 categories. In selecting Adherium as Most Innovative Hi-Tech Hardware Product, the international judges said, “Adherium has […]
Avita Medical initiates legal proceedings to cancel Renovacare patent
/in Avita Medical, Portfolio CompaniesValencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has filed an Inter Partes Review (IPR) petition against US Patent No. 9,610,430 (the ‘430 patent) owned by Renovacare Sciences Corp., as […]
AmpliPhi Biosciences Announces Closing of Public Offering
/in Portfolio CompaniesWednesday, May 10, 2017 5:29 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its previously announced underwritten public offering. Total proceeds […]
Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario
/in Avita Medical, Portfolio CompaniesValencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 10 May 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, has received notification of the initial FDA review of the Pre-EUA (Emergency Use Authorization) submission to allow the emergency deployment of its […]
AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants
/in Portfolio CompaniesThursday, May 4, 2017 10:02 pm EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an underwritten public offering of 6,956,522 shares of […]
AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections
/in Armata Pharmaceuticals, Portfolio CompaniesMonday, May 1, 2017 6:50 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “stated that the clinical safety and effectiveness data collected during development, including from emergency case studies, could inform future discussions for clinical development and, ultimately, the regulatory pathway to approval.” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: […]
‘The enemy of my enemy is my friend:’ Couple turns to viruses to beat back superbug
/in Portfolio CompaniesMan with desperate infection rescued 100 years after Canadian co-discovery of phages By Amina Zafar, CBC News Posted: Apr 28, 2017 8:14 PM ET Last Updated: Apr 29, 2017 7:32 AM ET – Link here It may seem like an unlikely option, but it was viruses that helped to save Tom Patterson when a superbug threatened his life. Patterson fell […]
AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference
/in Portfolio CompaniesTuesday, April 25, 2017 6:50 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “Intravenous applications of phage therapy to treat a terminally ill patient who was infected with a multidrug-resistant A. baumannii” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant […]